zed cases of
transmission of vCJD by transfusion of blood donated by persons incubating
the disease. Transfusion transmission appears to be highly efficient in
humans and animals. The 2006 National CJD Surveillance Unit report
concluded that "the incidence of vCJD may increase again, particularly if
different genetic subgroups are found but with longer incubation periods".
Abnormal prion proteins are an essential component of vCJD infectivity and
may be the only component. The adsorption of prion proteins by PRDT ligands
removes vCJD infectivity.
For additional information please refer to the following articles:
Gregori L, Lambert BC, Gurgel P et al. Reduction of transmissible
spongiform encephalopathy infectivity from human red blood cells with prion
protein affinity ligand. Transfusion 2006; 46:1152-1161
Wroe SJ, Pal S, Siddique D, et al. Clinical presentation and pre-mortem
diagnosis of variant Creutzfeldt-Jakob disease associated with blood
transfusion : a case report. Lancet 2006; 368:2061-67
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. ("ProMetic") (http://www.prometic.com) is a
biopharmaceutical company specialized in the research, development,
manufacture and marketing of a variety of commercial applications derived
from its proprietary Mimetic Ligand(TM) technology. This technology is used
in large-scale purification of biologics and the elimination of pathogens.
ProMetic is also active in therapeutic drug development with the mission to
bring to market effective, innovative, lower cost, less toxic products for
the treatment of hematology and cancer. Its drug discovery platform is
focused on replacing complex, expensive proteins with synthetic "drug-like"
protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D
facilities in the U.K., the U.S. and Canada, manufacturing
Page: 1 2 3 4 5 6 7 Related biology technology :1
|SOURCE PROMETIC LIFE SCIENCES INC.|
Copyright©2008 PR Newswire.
All rights reserved
. Prometic to present at the American Chemical Society2
. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia3
. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia4
. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products5
. ProMetic provides business update - Over $35 million worth of business secured in January6
. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use7
. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies8
. PerOs obtains USDA Establishment and Product Licenses for its oral vaccine formulations9
. China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing10
. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System11
. Genelex Corporation Defends Consumers Right to Obtain DNA Information: